Minerva

Minerva Gimenez Y Ribotta, Alicante ES

Patent application number	Description	Published
20100098664	Lentiviral vectors allowing RNAi mediated inhibition of GFAP and vimentin expression - The present invention relates to method for preventing, treating or alleviating a central nervous system (CNS) disorder using a non replicative lentivirus comprising a lentiviral genome comprising a nucleic acid sequence producing at least one functional miRNA, at least one functional shRNA and/or at least one functional siRNA, preferably derived from said shRNA, said miRNA, shRNA or siRNA being designed to silence the expression of a gene that encodes a protein of the astrocyte cytoskeleton. The present invention further relates to compositions and kits comprising such a lentivirus as well as to uses thereof.	04-22-2010

Patent application number	Description	Published
20100120112	Process of Improved Semi-Static Composting for the Production of a Humectant Substrate of Low Density of Use Thereof in Nurseries and Greenhouses - This invention includes the improved composting of cane sugar press mud and lignocellulosic materials. The result is a low density humectant substrate (LDHS) for the application in agriculture. The process is developed in homogenized and aerated mechanically semi-static biopiles. The lignocellulose materials are added in a fed batch system, in stages and doses which depend on the type of lignocellulosic material and the quality of required final substrate.	05-13-2010

Patent application number	Description	Published
20090104223	Method for Obtaining Antigenic Aggregates and the Use Thereof in Formulations - The invention relates to a method for obtaining aggregated antigenic structures that are capable of enhancing an immune response to aggregate antigens administered systemically and/or mucosally generating powerful immune response and to the chemical structures resulting from the application of said method, to the formulations obtained from such structures and their use. The method describes the obtention of novel aggregate antigenic structures by using aggregating, delipidating or oxidating agents or compounds enabling the release of lipids from the particles and their heterogeneous aggregation, wherein aggregates with particle sizes of between 30 and 500 nm are subsequently selected by means of a molecular exclusion process. The aggregation state can also be provoket inside the yeast by changing incubation conditions. The resulting structures can be used conveniently adjuvated or in a formulation in which several antigens can be introduced, wherein synergism between said components is found with respect to the immunogenicity of the response obtained. The preparation may also contain stabilizers and preservatives. The resulting antigenic structures can be used in the pharmaceutical industry as preventive or therapeutic vaccine formulation both for human and veterinary use and as part of diagnostic system.	04-23-2009